BNP Paribas Financial Markets
ELTX icon

BNP Paribas Financial Markets’s Elicio Therapeutics ELTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.1K Sell
2,072
-4,272
-67% -$42.9K ﹤0.01% 5407
2026
Q1 		$67.8K Buy
6,344
+676
+12% +$6.53K ﹤0.01% 4554
2025
Q4 		$45.1K Buy
+5,668
New +$51.4K ﹤0.01% 4727
2025
Q3 		– Sell
-82
Closed -$633 – 5611
2025
Q2 		$633 Buy
82
+17
+26% +$106 ﹤0.01% 5201
2025
Q1 		$400 Hold
65
– – ﹤0.01% 5158
2024
Q4 		$332 Buy
+65
New +$320 ﹤0.01% 5209

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets's ELTX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Elicio Therapeutics (ELTX) stake by 67% in Q2 2026, selling an estimated $42.9K and leaving 2,072 shares worth $8.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5407.

BNP Paribas Financial Markets first reported a position in ELTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $67.8K in Q1 2026. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • BNP Paribas Financial Markets held 2,072 shares of Elicio Therapeutics worth $8.1K as of Q2 2026.
  • BNP Paribas Financial Markets sold 4,272 Elicio Therapeutics shares in Q2 2026, an estimated $42.9K.
  • Elicio Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5407 holding.
  • BNP Paribas Financial Markets first reported a position in Elicio Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • BNP Paribas Financial Markets's Elicio Therapeutics position peaked at $67.8K in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.